R1507
R1507
R1507 is a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R), a protein that plays a crucial role in the growth and survival of cancer cells. This therapeutic agent has been investigated for its potential use in treating various types of cancer, including sarcomas and other solid tumors.
Mechanism of Action[edit | edit source]
R1507 functions by binding to the IGF-1R on the surface of cancer cells. The IGF-1R is a receptor tyrosine kinase that, when activated by its ligands (IGF-1 and IGF-2), triggers a signaling cascade promoting cell proliferation and inhibiting apoptosis. By blocking this receptor, R1507 prevents the activation of downstream signaling pathways such as the PI3K/AKT and MAPK pathways, which are critical for cancer cell growth and survival.
Clinical Development[edit | edit source]
R1507 has undergone several clinical trials to evaluate its efficacy and safety in cancer treatment. Early-phase trials have shown that R1507 is well-tolerated and has activity in certain types of cancer, particularly in patients with Ewing's sarcoma and other IGF-1R-expressing tumors.
Efficacy[edit | edit source]
In clinical studies, R1507 demonstrated antitumor activity in patients with Ewing's sarcoma, a rare type of cancer that occurs in bones or in the soft tissue around the bones. The response rates varied, with some patients experiencing partial responses or stable disease.
Safety[edit | edit source]
R1507 was generally well-tolerated in clinical trials. The most common adverse effects included fatigue, nausea, and infusion-related reactions. Serious adverse events were rare but included hypersensitivity reactions and hyperglycemia, which are consistent with the inhibition of the IGF-1R pathway.
Challenges and Future Directions[edit | edit source]
Despite the initial promise, the development of R1507 and other IGF-1R inhibitors has faced challenges. Resistance mechanisms, such as compensatory activation of alternative pathways, have limited the efficacy of IGF-1R-targeted therapies. Ongoing research is focused on identifying biomarkers for response and combining IGF-1R inhibitors with other therapeutic agents to overcome resistance.
Also see[edit | edit source]
- Monoclonal antibody therapy
- Insulin-like growth factor 1 receptor
- Ewing's sarcoma
- Cancer immunotherapy
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
